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Background: Human α-synuclein is a small-sized, natively unfolded protein that in fibrillar form is the primary
component of Lewy bodies, the pathological hallmark of Parkinson’s disease. Experimental evidence suggests that
α-synuclein aggregation is the key event that triggers neurotoxicity although additional findings have proposed a
protective role of α-synuclein against oxidative stress. One way to address the mechanism of this protective action
is to evaluate α-synuclein-mediated protection by delivering this protein inside cells using a chimeric protein fused
with the Tat-transduction domain of HIV Tat, named TAT-α-synuclein.
Results: A reliable protocol was designed to efficiently express and purify two different forms of human α-synuclein.
The synthetic cDNAs encoding for the native α-synuclein and the fusion protein with the transduction domain of Tat
protein from HIV were overexpressed in a BL21(DE3) E. coli strain as His-tagged proteins. The recombinant proteins
largely localized (≥ 85%) to the periplasmic space. By using a quick purification protocol, based on recovery of
periplasmic space content and metal-chelating chromatography, the recombinant α-synuclein protein forms could be
purified in a single step to ≥ 95% purity. Both α-synuclein recombinant proteins form fibrils and the TAT-α-synuclein is
also cytotoxic in the micromolar concentration range.
Conclusions: To further characterize the molecular mechanisms of α-synuclein neurotoxicity both in vitro and in vivo
and to evaluate the relevance of extracellular α-synuclein for the pathogenesis and progression of Parkinson’s disease, a
suitable method to produce different high-quality forms of this pathological protein is required. Our optimized
expression and purification procedure offers an easier and faster means of producing different forms (i.e., both the
native and the TAT-fusion form) of soluble recombinant α-synuclein than previously described procedures.
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Human α-synuclein (AS) is a 140-residue, natively unfolded
protein that in fibrillar form is the primary component of
Lewy bodies, the pathological hallmark of Parkinson’s dis-
ease (PD) [1]. PD is the second most common neurodegen-
erative disease resulting from the loss of dopaminergic
neurons in the brain: it affects ≈ 2% of the population over
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reproduction in any medium, provided the orA structural and physiological understanding of AS fi-
brils at the molecular level is critical for finding cures for
PD. Some evidence suggests that AS aggregation is the
key event that triggers AS-mediated neurotoxicity [2,3].
However, other experimental data proposed a protective
role of AS against oxidative stress (a major feature of PD)
[4]. To investigate the exact mechanism underlying this
protective action, as well as the role of AS pathogenetic
mutations, different research groups developed in vitro
models of oxidative stress based on the exposure of selected
cells to stress (e.g., hydrogen peroxide, 6-hydroxydopamine,
or serum deprivation) and evaluated AS-mediated protection
by delivering AS inside cells using the fusion protein TAT-
AS (for details, see below) [5]. These studies establishedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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stress and increased Hsp70 protein levels, whereas micro-
molar amounts of the protein were intrinsically toxic to
cells and decreased Hsp70 at the protein level.
Recombinant AS has been produced in Escherichia
coli since 1994 [6] by different methods which employ
whole-cells extract as the protein source [7], followed by
ammonium sulfate or acid precipitation and successive
chromatographic steps [8,9]. Alternative strategies are
based on the design of fusion proteins - for example,
with the glutathione S-transferase or the chitin binding
domain - and the use of specific enzymes for releasing
the fused AS [10,11]. Most recently, AS has been over-
expressed within E. coli periplasm and from this compart-
ment it was recovered in the native form by only two
purification steps [12]. AS was also produced as recombin-
ant protein fused with transduction domain of Tat protein
from HIV. In fact, it was demonstrated that heterologous
proteins chemically crosslinked to a domain of Tat protein
from HIV were able to transduce into cells [13]: accord-
ingly, this method become widely used because full-length
proteins can be rapidly introduced into primary and im-
mortalized cells. The fusion proteins can be directly added
to cell culture [14,15] or injected in vivo into mice [16]. Pro-
tein transduction occurs in a concentration-dependent
manner, requires at least one hour to achieve maximum
intracellular concentrations with nearly equal intracellular
concentrations among all cells in the transduced population
and the uptake does not depend on the cell type used
[17,18]. The technology requires the synthesis of a fusion
protein, linking the transduction domain (the minimal
transduction domain is represented by residues 47–57 of
HIV Tat, named TAT) [16] to the molecule of interest by
using a bacterial expression vector, followed by the purifica-
tion of this fusion protein under either soluble or denatur-
ing conditions. For a review, see [19,20]. TAT-AS was
previously produced by expressing pTAT/pTAT-HA in a
BL21(DE3)pLysS E. coli strain [5]. It was purified from a
washed bacterial pellet suspended in 8 M urea followed by
metal affinity chromatography on a Ni-NTA chelating
column because of the hexahistidine tag added during
the cloning procedure, following the guidelines reported
in [17].
To provide a tool to further characterize the molecular
mechanisms of AS neurotoxicity both in vitro and in vivo
and to evaluate the relevance for PD pathogenesis and
progression of extracellular AS, we focused on setting up
a fast, simple, and inexpensive method of producing high-
quality AS, both the native and the TAT-fusion AS form.
Results and discussion
Expression of recombinant AS in E. coli
Synthetic cDNA encoding for native or TAT-AS (GenBank
code KC609369 and KC609370, respectively) was subclonedinto pET11a plasmid, giving a construct encoding for a
protein that was 148- and 170-amino acids in length (AS
or TAT-AS, of 15.5 or 17.8 kDa), both containing an
N-terminal His-tag.
In order to optimize AS expression, several experi-
mental parameters were modified at the flask scale using
LB medium: IPTG concentration (0, 0.1, or 0.5 mM),
growth phase at induction (OD600nm = 0.4 or 0.8), and
time of cell harvest after adding IPTG (up to 24 hours).
Varying incubation times after adding IPTG significantly
affects expression of both AS recombinant forms obtaining
maximum protein production after five hours interval;
no AS production is observed before IPTG is added
(Additional file 1: Figure S1). Comparatively slightly higher
(≈ 1.3-fold) amounts of AS are produced if expression is
induced at an OD600nm ≈ 0.4 than at the later exponential
phase of growth. No increase in AS expression level was
observed using a richer medium (i.e. YT and SB media) or
decreasing the temperature of growth after IPTG addition.
The latter observation agrees with previous studies that
reported the highest production of recombinant AS at
37°C [12,21]: the rationale for the lack of temperature
dependence is probably an effect of the small size of the
investigated protein [22]. Taken together, Western blot
analysis shows that the highest production of both na-
tive AS and TAT-AS in E. coli (≈ 35 and 22 mg per
liter of fermentation broth, respectively) is observed by
growing the cells in LB medium to an OD600nm = 0.4,
adding 0.1 mM IPTG, and growing for another 5 hours
at 37°C. The best conditions set-up was then scaled up
to a 2-L flask level containing 500 mL of LB broth.
The overexpressed native and TAT-AS are largely
(≥ 85%) produced as soluble proteins, as demonstrated by
SDS-PAGE of soluble and insoluble cell content following
sonication (Additional file 1: Figure S2A). Indeed, recom-
binant AS is largely targeted to the periplasmic space
where it represents ≈ 70% of the whole protein content
(Additional file 1: Figure S2B). In fact, although no signal
sequence is apparent for translocation into the periplasmic
space, the C-terminal 99-to-140 portion of the protein plays
a signal-like role, cooperating with the central 61-to-95
protein region [23].
Purification and characterization of recombinant AS
Starting from 2 L of fermentation broth, native AS was
purified by employing only two steps: osmotic shock to
recover the periplasmic space content followed by chro-
matography on a HiTrap chelating column. As shown in
Figure 1A, following preliminary washing steps at 5-10%
of elution buffer (i.e., 25–50 mM imidazole), the recom-
binant AS is eluted at 100% of elution buffer as a single,
narrow peak. An overall yield of ≈ 16 mg native AS/L of
fermentation broth is achieved with a > 95% purity of
the final preparation as judged by SDS–PAGE (Figure 1B).
Figure 1 Representative purification of recombinant native AS on HiTrap chelating column (5 mL). A) An amount of periplasmic sample
corresponding to 2 L of fermentation broth was loaded and eluted in 20 mM sodium phosphate, pH 7.4, 1 M NaCl. Following two washing steps
at 5 and 10% of elution buffer to remove proteins aspecifically bound to the column, AS was eluted with 500 mM imidazole in 20 mM sodium
phosphate, pH 7.4 (elution buffer). B) SDS-PAGE analysis of fractions eluted from HiTrap chelating column. P and PS: cell pellet after osmotic shock and
periplasmic space content (both corresponding to 0.2 mL of fermentation broth); 0%, 5% and 100%: fractions eluted at different percentage of elution
buffer; M: molecular mass standard proteins (GE Healthcare). TAT-AS: purified TAT-AS recombinant protein eluted at 100% of elution buffer.
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gree under the same experimental conditions (> 95%, see
Figure 1B) and gave a yield of up to 12 mg/L of fermenta-
tion broth (Table 1).
The endotoxins (lipopolysaccharides) were completely
eliminated from the final protein preparation by treating it
with Triton X-114 (see Methods section) as assessed by the
E-TOXATE test. The absence of the detergent in the final
AS sample was apparent from the absorbance spectrum,
which showed a maximum at 276 nm (Figure 2A).
The intrinsic fluorescence spectrum of purified re-
combinant AS showed a maximum emission at 305 nm
(Figure 2B), as reported previously [24]. The circular di-
chroism spectrum of both purified AS forms presented
a strong negative peak at 202 nm and a small shoulder
at around 222 nm (Figure 2C), indicating a random coil
structure possibly with short, marginally stable α-helices;
see also [25].
AS is known to be a monomer using nondissociating
PAGE [8] but it elutes in size-exclusion chromatography
as a symmetric peak at a position corresponding to a
larger apparent molecular mass [26]. Gel-permeation
chromatography of purified recombinant native AS and
TAT-AS gave a main peak at 61.5 ± 5.4 kDa (expressed
as mean ± SD, n = 4, Figure 3): the abnormal behaviorTable 1 Purification of native AS and TAT-AS from E. coli star
Purification step Total protein (mg)
Whole cell extract c 210 [185] d
Osmotic shock 40 [29] d
HiTrap chromatography 16 [11.8] e
The value obtained for the purification of TAT-AS is shown in brackets.
a The purity of AS at each step of purification was estimated by SDS–PAGE.
b Ratio of the amount of AS obtained at each step to the total amount of AS estima
c Supernatant of the cell lysate by sonication.
d Determined by Bradford assay with bovine serum albumin as a standard.
e Determined spectrophotometrically.of AS in size-exclusion chromatography has been ascribed
to its natively unfolded conformation in physiological buf-
fer [8]. Indeed, an additional minor peak (≈ 14% of the
main peak) corresponding to an apparent molecular mass
of 130 ± 8 kDa was also apparent: both peaks gave a single
band at 18 kDa in SDS-PAGE analysis (inset of Figure 3).
The peak at lower elution volume was previously demon-
strated to correspond to a dimer of AS due to disulfide
bond formation between cysteines at position 136 under
non-reducing conditions [27]. Misincorporation of Cys
instead of Tyr at position 136 was reported to happen in
AS with a 20-25% frequency: because of the reducing
environment of the final cellular destination, dimeric
AS should convert into the monomeric form thus not
affecting the cell assay.
Atomic force microscopy and functional evaluation of
purified AS
AS is natively unfolded and prone to aggregation. To
evaluate the fibrillogenic propensity of purified AS, we
incubated AS (both native and TAT) for increasing time
intervals (2 up to 7 days) at 37°C with sporadic mild agi-
tation. Aliquots of the preparations were then analyzed
by atomic force microscopy (AFM). Starting from day 2
and up to day 3, we observed AS aggregation with clearlyting from 1 L culture (≈ 2.5 g cell paste)
AS (mg) AS purity a (%) Yield b (%)
35 [22.2] 16.7 [12.0] 100 [100]
30 [20] 75 [69] 85 [90.1]
16 [11.8] > 95 [> 95] 53 [59]
ted in the whole cell extract.
Figure 2 Spectral properties of recombinant native AS. In 20 mM
potassium phosphate buffer, pH 7.4, 150 mM sodium chloride, after
eliminating endotoxins. A) UV–vis Absorbance spectrum of AS,
3.2 mg/mL, 15°C. B) Protein fluorescence of AS; 0.1 mg/mL,
excitation at 280 nm. C) Far-UV circular dichroism spectrum of
AS; 0.1 mg/mL.
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incubation times. Qualitatively, the TAT-fused AS form
seems more fibrillogenic than the native counterpart
(Figure 4A).
To functionally assess the purified AS, we performed
a toxicity assay on SHSY-5Y cells. Cells were incubated
with increasing amounts of AS (both native and TAT)
for 24 hours; then viability was measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTS) colorimetric assay (Figure 4B-C). We confirmed
the toxicity of TAT-AS whereas the native form had no
toxic effect in this kind of assay, as previously reported
[5]. The basic toxicity of TAT-AS might be a starting
point for experiments aimed at unraveling the relation
between AS and other kind of cellular stressors, for in-
stance oxidative stress, proteasome impairment or autoph-
agy, all features potentially linked to PD etiopathogenesis
[28-31].
Conclusions
Mammalian cells can be manipulated by transfecting ex-
pression vectors, microinjection, or diffusion of peptidyl
mimetics: these approaches have been rather successful
but are not easily regulated and can be laborious. One
approach to circumvent these problems is to use HIVFigure 3 Gel permeation analysis of recombinant TAT-AS. Peak 1
corresponds to an apparent molecular mass of 130 ± 8 kDa and peak 2
corresponds to an apparent molecular mass of 61.4 ± 5.4 kDa; both
peaks gave a single band at 18 kDa in SDS-PAGE analysis (inset).
Conditions: HiLoad 16/60 Superdex 200 (GE Healthcare) column;
20 mM potassium phosphate buffer, pH 7.4, 150 mM sodium chloride
as elution buffer.
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Figure 4 Functional validation of purified AS. A) Atomic force microscopy (AFM) of native AS and TAT-AS. AS was incubated as described in
Methods to trigger aggregation and fibrillogenesis. At day 3, arrows highlight oligomeric species, while at day 7 they point to longer fibrils.
B-C) Cell toxicity assay of purified AS. SHSY-5Y cells were exposed to increasing amounts of AS native (B) or TAT-AS (C) for 24 hours; then
cell viability was measured by MTT colorimetric test. Each experimental condition was conducted in quadruplicate. CTRL: control; *p<0.05;
**p<0.01, one-way ANOVA and Tukey’s post-hoc test.
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by [32,33]. We report on the expression and purification
of AS, a protein implicated in PD, which exists as a na-
tively unfolded protein in physiological buffer. Here, a
new protocol for preparing recombinant native AS and
TAT-AS has been developed that involves two steps only:
(1) osmotic shock for release of AS-containing periplasm
fraction and (2) HiTrap chelating chromatography for
further purification of AS. Previous methods used to
produce recombinant native AS in E. coli required more
steps, comprising at least one ammonium sulphate precipi-
tation and two chromatographic separations [12,21,27].Noteworthy, and differently from previously reported
methods [17], TAT-AS was largely produced as soluble
protein thus avoiding the need for a resolubilization
step. This result is due to a controlled rate of protein
synthesis – because of the low IPTG concentration
added at the exponential phase of growth – and to the
efficient targeting of TAT-AS to the periplasmic space.
The latter is not an artifact of massive overproduction
or of the experimental method of osmotic shock: AS in
the periplasm of E. coli exists stably in (largely) disor-
dered monomeric form [23]. The secondary, tertiary, and
(apparent) quaternary structures of both native and TAT-
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Indeed, both recombinant AS proteins form fibrils and
TAT-AS only shows cytotoxic effects on SHSY-5Y cells.
This new protocol is a convenient, economical, and
rapid procedure for preparing different forms of AS, which
favourably compares to methods currently being used.
About 12–16 mg AS (native and TAT-fusion protein) with
95% purity can be regularly prepared from a 1-L culture in
1 day. AS is also commercially available (at a cost > 600
$/mg protein) but its variant forms (such as the TAT-AS
required for advanced studies) are not.
In conclusion, the recombinant AS forms produced
here represent a useful tool for in vitro or in vivo experi-
ments where a tight control of AS concentration and
intracellular or extracellular localization is mandatory.
Moreover, the capability of native AS and TAT-AS to
aggregate and form oligomers or fibrils, though with dif-
ferent toxic effect on our cell model, is of pivotal import-
ance in order to discriminate the real toxic intermediate
and the relevance of cellular localization in the dynamics
of AS aggregation, toxicity and cell-to-cell propagation, a
still debated question in the field of PD pathophysiology.
Methods
Design and cloning of AS cDNAs
Two synthetic cDNAs for AS (one encoding for the native
protein and the second containing the additional sequence
encoding for the Tat transduction domain, GenBank code
KC609369 and KC609370, respectively) were designed by
in silico back translation of the amino acid sequence
reported in the data bank (GenBank accession number
NM_001146055.1, α-syn gene) and optimizing the codon
usage for E. coli expression. In detail, all AAG codons
(encoding for Lys) were converted into AAA; all CTT,
CTC, and TTG codons (encoding for Leu) were converted
into CTG; one GGA codon (encoding for Gly) was
converted into GGT; and one GTG codon (encoding for
Val) was converted into GTT. In order to facilitate the
subcloning into pET11a plasmid (carrying the resistance
to ampicillin, Novagen), NdeI (CATATG) and BamHI
(GGATCC) sites were added at the 5’- and 3’-ends of
the cDNA, respectively, and a sequence encoding for
six additional histidines was added to the 5’-terminal
end of both AS protein forms. The α-syn cDNAs were
inserted in the pET11a vector using NdeI and BamHI
sites, giving 6.088- and 6.154-kb constructs (pET11-AS
and pET11-TAT-AS, respectively).
Strains and growth conditions
For protein expression, both recombinant plasmids were
transferred to the E. coli host BL21(DE3) strain: starter
cultures were prepared from a single recombinant E. coli
clone in LB medium containing ampicillin (100 μg/mL
final concentration). Expression trials were conductedusing baffled (500 mL) Erlenmeyer flasks containing
100 mL of LB, SB or YT medium that was inoculated
with the starter culture (initial OD600nm = 0.05); cells
were grown at 37°C and shaken (180 rpm) until the
protein expression was induced by adding IPTG. Crude
extracts were prepared by sonication; see [34] for de-
tails. The insoluble fraction of the lysate was removed
by centrifugation at 39,000 g for 1 hour at 4°C. Expres-
sion level of AS was assessed by SDS-PAGE and Western
blot analysis; see below.
For protein purification, periplasmic space content
was recovered by adding 50 mL of osmotic shock buffer
(30 mM TrisHCl, pH 7.2, 40% saccharose, 2 mM EDTA)
to 2.5 g of cell paste (from 1 L of fermentation broth)
and incubating for 10 min at room temperature; cells
were collected by centrifugation at 17,200 g for 20 min
and the pellet was quickly dissolved in 45 mL of cold
1 mM MgCl2. The protein content of the periplasmic
space was released and after 3 min at 4°C collected by
centrifugation at 17,200 g for 20 min. To the soluble
extract 5 mL of 200 mM sodium phosphate was added,
pH 7.4, containing 20 μg/mL leupeptin, 7 μg/mL pepstatin,
and 1.9 μg/mL PMSF.
Purification of the recombinant AS
Both recombinant AS forms containing an N-terminal His-
tag were purified from soluble extracts using Ni2+-affinity
chromatography (HiTrap Chelating HP columns, GE
Healthcare) equilibrated with 20 mM sodium phos-
phate, pH 7.4, 1 M NaCl. The bound protein was eluted
with 500 mM imidazole in 20 mM sodium phosphate,
pH 7.4. Imidazole was then removed by overnight dialy-
sis at 4°C against 20 mM sodium phosphate buffer,
pH 7.4, 150 mM sodium chloride.
The amount of purified AS was determined using the
extinction coefficient at 280 nm of 5960 M-1 cm-1 for
native AS and of 7450 M-1 cm-1 for TAT-AS. The amount
and purity degree of the final AS preparations were also
estimated by SDS-PAGE and densitometric analysis
using the software Quantity One (Biorad). Recombinant
AS was analyzed by Western blot using anti-His-tag
mouse monoclonal antibodies (His-probe, Santa Cruz
Biotechnology) and goat anti-mouse IgG HRP-conjugated
antibodies (Jackson ImmunoResearch) [34,35]. Recogni-
tion was confirmed by employing a chemiluminescent
test (ECL Plus Western Blotting Detection System, GE
Healthcare), using His-tagged D-amino acid oxidase as
positive control [36].
Safety precautions during production and managing
of TAT-AS were as detailed in [17].
Endotoxins were removed from the final AS preparation
according to the procedure suggested by [37]. Briefly, 1%
Triton X-114 was added to the protein sample, which was
incubated at 4°C for 30 min and then at 37°C for 10 min,
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fraction was recovered and the incubation at 37°C, the
centrifugation step, and recovery of aqueous fraction were
repeated until Triton X-114 was completely eliminated.
The removal of endotoxins was assessed by the E-TOXATE
test (Sigma-Aldrich).Biochemical characterization of recombinant AS
UV-Visible absorption spectra were recorded with a Jasco
V-560 spectrophotometer (Jasco Co., Cremello Italy). Cir-
cular dichroism spectra were recorded on a J-810 Jasco
spectropolarimeter and analyzed by means of Jasco soft-
ware; cell pathlength was 0.1 cm for measurements in the
190- to 250-nm region (0.1 mg protein/mL) [38]. All mea-
surements were carried out at 15°C in 20 mM sodium
phosphate, pH 7.4, 150 mM sodium chloride. Baseline was
corrected to account for the buffer content. Circular di-
chroism spectra were analyzed by K2d software [39].
Size-exclusion chromatography was performed at room
temperature on a Superdex 200 or HiLoad Superdex 200
(GE Healthcare) column by means of an Äkta chromato-
graphic system (Amersham Pharmacia Biotech), using
20 mM potassium phosphate, pH 7.4, 150 mM sodium
chloride, as elution buffer. The column was calibrated
with suitable standard proteins.Atomic force microscopy
AS 130 μM was incubated at 37°C for increasing time
intervals (2, 3 and 7 days). Each sample was diluted to
50 μM with 10 mM phosphate-buffered saline, pH 7.4,
and incubated for 0.5 min on a freshly cleaved Muscovite
mica disk. After the incubation period, the disk was washed
with H2O and dried under a gentle stream of nitrogen.
The sample was mounted onto a Multimode AFM with
a NanoScope V system operating in Tapping Mode using
standard phosphorus-doped silicon probes (T: 3.5–4.5 lm,
L: 115–135 lm, W: 30–40 lm, K: 20–80 N/m) (Veeco
Instruments, Plainview, NY, USA).AS cell toxicity assay
SHSY-5Y cells were cultured at 37°C, 5% CO2 in D-MEM
supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine, 100 IU/mL penicillin, and 100 μg/mL
streptomycin (Invitrogen, Carlsbad, CA, USA). Then, 3 x
104 cells were seeded in a 96-well plate and incubated over-
night. The next day, the medium was changed and the
toxicity of AS was assessed by adding increasing
amounts at the μM scale of the purified protein (both
native and TAT) for 24 hours. Then, cell viability was
measured by a MTT-based assay according to the
manufacturer’s instructions (Promega Corp., Madison,
WI, USA).Additional file
Additional file 1: Figure S1. Analysis of expression of TAT-AS in BL21
(DE3) E. coli cells by means of Western blot. Protein expression was
induced at an OD600nm = 0.4, adding 0.1 mM IPTG; the cells were then
grown for the time indicated at 37 °C. Figure S2. Subcellular distribution
of AS forms overexpressed on E. coli. A) SDS-PAGE analysis of protein
content in whole cell fraction (C), crude extract (following sonication and
centrifugation, CE) and pellet (insoluble fraction, P) of BL21(DE3) E. coli
cells expressing native AS (left) or TAT-AS (right). B) Subcellular
distribution of overexpressed AS forms: (C) whole cell fraction, (PS)
periplasmic space.
Abbreviations
AFM: Atomic force microscopy; AS: α-synuclein; MTT: 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide; PD: Parkinson’s disease; TAT-AS: chimeric
α-synuclein protein fused with the Tat-transduction domain of HIV Tat.
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